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Abstract Based on recent developments in glioblastoma sub-
typing, we examined DARPP32 (PPP1R1B), a neuronal
marker against STAT5 and STAT3 that are pro-oncogenic in
glioblastoma. mRNA ratios of DARPP32, STAT1, STAT3,
STAT5A and STAT5B were assessed in routinely diagnosed
gliomas s including a series of glioblastomas from patients
(n067) treated with chemoradiotherapy (temozolomide), out
of which 88 % had sequencing validated IDH-negative dis-
ease. DARPP32/STAT1 (p00.0007), DARPP32/STAT3 (p0
0.0004) and DARPP32/STAT5B (p00.0039) ratios were sig-
nificantly higher in grade II and III as compared to grade IV
tumours. The same high ratios were also associated with
absence of immunohistochemically assessed AKT/PKB phos-
phorylation and survivin protein expression. High DARPP32/
STAT3, DARPP32/STAT5B, and STAT5B/STAT3 ratios were
associated with longer patient progression free (PFS) and
overall survival (OS). Upon multivariate analysis, total/subto-
tal removal of the tumour (HR:0.431; 95%CI:0.241–0.771,
Wald p00.005), high DARPP32/STAT5B (HR:0.341;
95%CI:0.169–0.690; Wald p00.003) and STAT5B/STAT3
mRNA ratios (HR:0.480; 95%CI:0.280–0.824; Wald p0
0.008) were independent favorable parameters for prolonged
PFS. Extent of surgery (HR:0.198; 95%CI:0.101–0.390; p<
0.001) and high DARPP32/STAT5A ratios (HR:0.320;
95%CI:0.160–0.638, p00.001) were independently predic-
tive for longer OS. The presented approach is applicable for
prospective validation and appears promising towards an ef-
fective glioblastoma patient stratification in addition to IDH
mutations. These data may contribute to understanding the
biology of gliomas with respect to their potential neuronal
characteristics and justify STAT-inhibiting therapeutic inter-
ventions in the same tumour system.
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Introduction
Diffuse gliomas, i.e., tumours with astrocytic, oligodendro-
cytic, ependymal or mixed cell characteristics, are the most
common primary brain tumours in adults and are catego-
rized with increasing grade of malignancy [1]. About 70 %
of gliomas are glioblastomas, WHO grade IV, aggressive
and currently incurable [2]. Gliomas are presumed to arise
from neural stem cells that exist in the brain. The acquisition
of IDH1 & 2 mutations in these progenitors is considered as
a major event in gliomagenesis [3, 4]. Gliomas developing
on an IDH-mutant background are usually of grade II or III
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with oligodendrocytic or astrocytic or mixed features, and
secondary glioblastomas, i.e., tumours with a known favor-
able outcome. The limited incidence (<5 %) of IDH1-
mutant de novo glioblastomas [5] that have a better progno-
sis than IDH-wild-type ones, presumably reflects a grade II–
IV series of events that have gone clinically unnoticed [6].
Hence, all evidence prompts for distinguishing gliomas into
IDH-mutant and IDH-wild type disease [6, 7]. Strikingly,
IDH-mutant disease is included in the proneural phenotype /
subtype [6, 8–10], while it largely overlaps with the meth-
ylator phenotype [11], all of which are also associated with a
better prognosis of gliomas. However, despite these insights
towards comprehending gliomagenesis and although stan-
dard treatment (resection, radiotherapy with concomitant
and adjuvant temozolomide) appears to benefit patients with
glioblastoma [12], the expected median survival is still 12–
15 months, while less than 10 % of patients, those with
favorable disease characteristics, survive for more than
5 years [13]. Hence, understanding the remaining more than
90 % of glioblastomas and finding alternative treatment
options for these patients remains a great challenge.
At the other end of the favorable proneural lies the
mesenchymal subtype with worst prognosis [8, 9]. Addi-
tional subtypes have been described between these two,
such as neural and classical [9], which are backed by spe-
cific genomic alterations [14], or proliferative [8], while
there is always space for new subtypes to be identified if
larger series are examined. As described [9], proneural
subtype resembles oligodendrocytes; neural, mainly astro-
cytes and neurons; classical, murine astrocytes; and, mesen-
chymal, cultured astroglia characterized by high motility,
invasiveness and angiogenic capacity. Main contributors to
the acquisition of the mesenchymal phenotype appear to be
C/EBPbeta and STAT3 [15]. STAT3 belongs to the Signal
Transducers and Activators of Transcription, a family of
transcription factors. STAT3 plays key roles in neural stem
cell and astrocyte development, and has been found to play
dual tumour suppressive and oncogenic roles in gliomas
depending on the mutational profile of the tumour (reviewed
in [16]). In addition, STAT3 inhibition sensitizes glioblasto-
ma cells to alkylating agents and EGFR inhibitors [17]. Less
is known about the role of other usually investigated mem-
bers of the STAT family in gliomas. Stat5b may be involved
in glioblastoma cell growth, cell cycle progression, invasion
and migration [18]. Stat1, a potent inhibitor of cell growth
and promoter of apoptosis, is ubiquitously expressed in glial
tumours, as well as in normal brain tissues [19].
With respect to the subtypes described above it is of interest
that neuronal characteristics were represented, except for the
neuronal subtype, in the classical and mesenchymal subtypes
as well, but not in the proneural one [9]. Herein, we profiled
neuronal vs. STAT gene expression in a series of gliomas and
associated these profiles with glioblastoma patient outcome.
As a neuronal marker we selected a molecule indicative of
early neuronal differentiation, PPP1R1B (protein phospha-
tase 1, regulatory (inhibitor) subunit 1B or dopamine and
cAMP-regulated neuronal phosphoprotein 32, DARPP32).
DARPP32 is a dual function protein that is capable of
inhibiting either protein phosphatase-1 or protein kinase-A,
according to the site it is phosphorylated and according to
the signal inducing its phosphorylation. DARPP32 is a
long known gene and protein [20] that is expressed in
most specialized structures in the normal brain [21].
DARPP32 has mainly been studied in the context of
central nervous system physiology and pharmacology
[22]. Initially regarded as a dopamine signalling mediator,
this molecule is currently considered as a signalling hub
molecule which may improve the general performance of
the neuronal circuits in which it is expressed (reviewed in
[23]). DARPP32 may also promote epithelial oncogenesis
(Beckler, Moskaluk et al. 2003), while its truncated iso-
form, t-DARPP, has been associated with resistance to
trastuzumab in breast cancer (Belkhiri, Dar et al. 2008).
However, full-length DARPP32 antagonizes t-DARPP tras-
tuzumab resistance [24], while in some epithelial cancers
DARPP32 may play tumour suppressive (Pimenta, Horta
et al. 2007) and migration inhibitory roles [25].
In addition to STAT1, STAT3, STAT5A, STAT5B and
DARPP32 mRNA profiles we also examined AKT/PKB
phosphorylation and survivin expression in glioma tissues.
These markers were chosen because DARPP32 protein is
induced through PI3K/AKT activation by the brain-derived
neurotrophic factor in the brain [26], while t-DARPP pro-
motes tumour cell growth by activating AKT [27]; and also
because STAT3 is essential for survivin expression [28, 29].
Materials and Methods
Tissue Material Previously diagnosed histologic material
from stereotactic biopsies and partial or complete resections
of gliomas (formalin-fixed paraffin-embedded tissues
[FFPE]) was retrieved from the archives of the Dept of
Pathology, Aristotle University of Thessaloniki School of
Medicine (n0135) and from the Tumour Tissue Repository
of the Hellenic Cooperative Oncology Group (HeCOG) (n0
70). Out of these 205 tumours, 187 tissue blocks were
evaluated as eligible for processing for molecular and im-
munohistochemical investigations based on adequacy of
material, as assessed upon histologic examination. Patient
demographic and tumour histologic characteristics are
shown in Table 1. With respect to de novo and secondary
glioblastomas, the latter were characterized as such (a) in the
case of known clinical history of a lower grade tumour, and
(b) when areas of grade III or II were present histologically
upon examination of all available tissue blocks. The above
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tumours were used for Tissue MicroArray (TMA) construc-
tion (2×1.5 mm cores per tumour) and for DNA and RNA
extraction. Morphologically non-neoplastic brain (NNBT)
tissue was available in eight cases in the same or in separate
tissue blocks and was also included in the TMAs.
Patients Clinical data were available for 67 patients with
glioblastoma that had been treated during various time peri-
ods (2005–2008) in the Dept of Medical Oncology, Aristotle
University of Thessaloniki School of Medicine and in the
Dept of Radiation Therapy, both located in Papageorgiou
Hospital (54 patients) or in a private clinic (13 patients). As
shown in Table 2, the extent of surgical removal of the
tumour was known in 65/67 cases. All patients were
chemo-naïve. Only one patient with clinically secondary
glioblastoma presented in this group; however, histological
assessment of all available tissue material showed additional
2 cases with grade II and III areas as described above.
Hence, the histologically de novo glioblastomas were 64
out of 67 (95.5 %). Except for two cases where early tumour
death occurred, all patients received the same initial treat-
ment with radiotherapy and concomitant temozolomide fol-
lowed by 6 months adjuvant temozolomide administration
(CCRT) [30]. Patients were followed every 3 months with
physical examination and brain MRI up to 46 months or
until death was reported. Upon relapse, patients (N022)
received 1st line chemotherapy (temozolomide [N07]; bev-
acizumab and irinotecan [N010]; BCNU and irinotecan
Table 1 Tumour demographic data and histologic characteristics
N (%)
All tumors 187






Astrocytic tumors 137 (94.5)
Oligodendrocytic/Mixed tumors 8 (5.5)
Grade II 14 (9.7)
Diffuse fibrillary astrocytoma 14 (100)
Grade III 18 (12.4)
Anaplastic astrocytoma 12 (66.7)
Anaplastic oligodendroglioma 1 (5.6)
Anaplastic oligoastrocytoma 5 (27.8)
Grade IV 113 (77.9)
Glioblastoma 111 (98.2)
Glioblastoma with oligodendrocytic component 2 (1.8)
De novo Glioblastomas 96/113(85.0)
Secondary Glioblastomas 17/113 (15.0)
aRQ relative mRNA quantification; in total, 77.5 % of available FFPE
samples yielded informative RNA measurements
Table 2 Patient / Tumour data for clinical associations
N (%)






Biopsy (including stereotactic biopsies) 17 (26.1)
Subtotal 34 (50.7)
Total 14 (20.9)
Missing info 2 (2.3)
Tumors, histology
glioblastoma 64 (95.5)
glioblastoma, secondary 3 (4.5)
MGMT promoter methylation
informative 54 (80.6 %)
unmethylated 34/54 (63.0 %)
methylated 20/54 (37.0 %)
IDH1 & IDH2 mutations
informative 61 (91.0 %)
mutant 2#/61 (3.3 %)
wild type 59/61 (96.7 %)
EGFR CN
informative 64 (95.5 %)
predicted CN >2.5 35/64 (56.3)
predicted CN ≤2.5 27/64 (43.7)
Treatment
CCRT (radiotherapy plus Temozolomide)a 65 (97.0)
Chemo Post CCRT
1st line chemotherapy 22 (32.8)
2nd line chemotherapy 7 (10.4)
OS (months)
Deaths 58 (86.6 %)
Median (95 % CI) 17.2 (13.3–21.1)
Range 0.7–45.6
PFS (months)
Events 61 (91.4 %)
Median (95 % CI) 9.6 (7.4–11.8)
Range 0.7–39.3
PFS-6 month
No progression in 6 months 51 (76.1)
Progression or death in 6 months 16 (23.9)
RQ relative mRNA quantification; # IDH1 p.R132G and p.R132H;
CN: copy number as assessed by CNV assays
a Two patients with early tumor death did not receive any treatment
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[N03]) with the addition of bevacizumab in one case. Upon
further relapse (N07), patients received erlotinib, irinotecan
and bevacizumab as 2nd line chemotherapy.
Written informed consent had been received by the
patients for the use of biologic material and the study was
approved by the Bioethics Committee of the School of
Medicine, Aristotle University of Thessaloniki under the
title: “Molecular and genetic markers associated with re-
sponse to combined radio/chemotherapy in patients with
glioblastoma” (approval #: A13723).
DNA and RNA from routinely processed formalin-fixed
paraffin-embedded tissues were extracted with standard pro-
cedures upon enrichment in tumour cells with macrodissec-
tion (>50 % tumour cells in the molecular sample in all
cases). For DNA extraction the QIAamp mini kit (Qiagen,
Hilden, D) was used, while for RNA extraction, overnight
paraffin tissue fragment lysis with proteinase K at 56 °C
followed by application of the TRIZOL-LS reagent (Life
Technologies, Paisley, UK) and reverse transcription with
random primers and the Superscript III system (Life Tech-
nologies). Commercial reagents were applied according to
the instructions of the manufacturers.
Relative Gene Expression was assessed with RTQ-PCR by
using premade Taqman-MGB assays in an ABI7500 system
(Applied Biosystems / Life Technologies) equipped with the
SDS v1.4 software by using the default conditions. The
assays used (NM reference, amplicon size, location) were:
for DARPP32, Hs00259967_m1 (NM_001242464.1,
NM_032192.3, NM_181505.3, 90 bp, exons 4–5); for
STAT1, Hs01014005_m1 (NM_007315.3, NM_139266.2,
67 bp, exons 3–4); for STAT3, Hs01047580_m1
(NM_003150.3, NM_139276.2, NM_213662.1, 87 bp,
e x o n s 3 – 4 ) ; f o r S TAT5A , H s 0 0 2 3 4 1 8 1 _m1
(NM_003152.3, 63 bp, exons 12–13); and, for STAT5B,
Hs00560035_m1 (NM_012448.3, 91 bp, exons 2–3).
GUSB (beta-glucuronidase, assay 4333767 F) was selected
as the endogenous reference because it does not seem to be
represented in pseudogenes and also because it has been
identified as one among the best preserved mRNA targets in
FFPE tissues [31, 32]. Relative quantification (RQ) analysis
was assessed according to the 2^-dCT method that can be
applied for small amplicons, whereby dCT 0 CTtarget—
CTGUSB. Samples were tested in 10 ul reactions and were
run in duplicates. Duplicate runs were also performed for 32
samples and yielded <1.5 cycles differences in ddCTs
(dCTrun1—dCTrun2) per sample and per assay, which would
correspond to < ±2-fold change in the evaluation of relative
gene expression (inter-run validation). Exclusion criteria for
RQ analysis were endogenous reference CT values higher
than 36 for each sample; and, dCTs higher than 0.5 per
duplicate pair. According to these criteria, in total 145/187
samples (77.5 %) were found eligible for further RQ
analysis.
In order to investigate combined effects of DARPP32/
STAT gene expression we also assessed RQ ratios for paired
gene expression by omitting GUSB. For example, RQ ratio
for DARPP32/STAT3 corresponded to 2^-ddCT, whereby
ddCT 0 (CTDARPP32—CTGUSB)—(CTSTAT3—CTGUSB).
This approach in fact annihilated reference gene bias for
single marker results. That is, changes in single marker
DARPP32 and STAT RQ values in one direction might be
due to GUSB expression aberrations in the opposite direc-
tion; this condition can not be excluded for any endogenous
reference, especially in paraffin samples where PCR effi-
ciency unpredictably varies.
Glioma DNA Markers MGMT promoter methylation, IDH1
and IDH2 mutations (exon 4 for both genes) and EGFR CN
(gene copy numbers) were assessed in tumour DNA sam-
ples from patients with known follow-up only (Table 2). For
MGMT, the SALSA MS-MLPA KIT ME011 (MRC-Hol-
land, Amsterdam, NL) was used, which included probes for
three distinct CpG-rich sites in the MGMT enhancer. Nor-
mal blood DNA and a reactive lymph node FFPE-DNA
sample were used as controls. Products were electrophor-
esed on an ABI3130 genetic analyzer (Applied Biosystems /
Life Technologies). This method gave informative results,
i.e., all picks present in the non-digested sample with ac-
ceptable method internal controls and reference probe
peaks, in 54/67 cases (80.6 %). The results were evaluated
according to [33]; relative peak values ≤0.25 were charac-
terized as unmethylated, relative peak values >0.25 as meth-
ylated; and, relative peak values >0.75 as completely
methylated. The procedure was repeated twice to assess
concordance of results (retention in the same category of
methylation status).
For mutation analysis, cycle-sequencing with BigDye®
Terminators v1.1 (Applied Biosystems) was performed on
the ABI3130XL genetic analyzer with the following primers
(sequences 5′-3) for IDH1 (nested PCR): forward (F), TCAC-
CAAATGGCACCATACGA, reverse (R) GTTGAGATG-
GACGCCTATT; Fn, ACCAAATGGCACCATACGA and
Rn, GCAAAATCACATTATTGCCAAC (348 bp →
164 bp); for IDH2: F, CCGTCTGGCTGTGTTGTTGCT, R,
AGACAAGAGGATGGCTAGGC (326 bp).
Copy number variation (CNV) was assessed with real time
PCR (ABI7900HT system) for the EGFR gene with the
Hs02822119_cn (exon 10) and the Hs01426560_cn (exon 2)
pre-designed TaqMan® Copy Number Assays (Applied Bio-
systems). The TaqMan® Copy Number Reference Assay RN-
ase P was used as endogenous reference. Reactions were run
in quadruplicates in an ABI7900HT system. Three normal
blood DNA samples were included in each run as calibrator
samples, along with a no-template control (NTC). Results
332 D. Televantou et al.
(predicted copy numbers) were obtained automatically with
the CopyCaller™ Software v1.0 in comparison to averaged
calibrator values upon setting the evaluation threshold at Ct0
32. Average predicted copy numbers higher than 2.5 were
considered as amplification.
Immunohistochemistry (IHC) was performed on 2 μm TMA
sections. Phosphorylation of Akt/PKB was investigated
with an anti-rabbit monoclonal antibody that detects phos-
phorylated Ser473 on Akt1 and on corresponding sites on
Akt2 and Akt3 proteins (#3787 L, clone 736E11, Cell
Signaling Technologies, Beverly, MA). Expression of survi-
vin (BIRC5) was assessed with an anti-mouse monoclonal
antibody (#M3624, clone 12C4, DAKO, Glostrup, DK). In
both cases, antibodies were diluted 1:50, DAKO Target
Retrieval Solution S1699 was used for Akt/PKB and
S2367 for survivin epitope unmasking, and anti-rabbit
(K4011) and anti-mouse (K4007) Envision systems were
used for target visualization. The cut-off for phospho-Akt
was set at 5 % of positive tumour cells [34]; nuclear and
cytoplasmic staining were separately assessed. With the
monoclonal antibody used, survivin expression was identi-
fied as intra-nuclear spots in very few glioma cells among
all grades, in accordance with observations in a variety of
tumours with this antibody [35] but other than reported in
former studies using different antibodies [36, 37]. Hence, a
cut-off of 1 % was used for survivin positivity. The reported
cytoplasmic positivity was not observed. Ki-67 staining
(clone MIB-1, DAKO) had also been applied in the diag-
nostic setting with standard procedures and with 3 % as cut-
off between low (II) and high (III and IV) grade tumours
[38]
Statistical Analysis Overall survival (OS) was calculated
from initial diagnosis until patient death or last contact.
Surviving patients were censored at the date of last contact.
Progression free survival (PFS) was defined as the time
interval between initial diagnosis and disease progression,
which was assessed with clinical examination and with MRI
(deaths without verified prior disease progression were also
considered as events in the calculation of PFS). Disease
progression was considered upon CCRT (initial treatment)
only, since treatment in the 1st line was heterogeneous. Log-
rank test was used to compare time to event distributions of
subgroups. Cox proportional hazards regression models
were used to assess the influence of the target genes exam-
ined on OS and PFS outcome.
Spearman’s rank correlation was used as a measure of
association between all tested targets. The Mann–Whitney
test was performed to compare mRNA RQ values with
nominal variables. Receiver operating characteristic (ROC)
curve analysis was performed to assess the relationship
between mRNA expression of genes (corresponding RQ
values) and 6-month progression free survival rate (PFS-
6 month), which was used as the criterion to assess patient
response [39]. For significant results (area under the curve
[AUC] >0.6), optimal cut-off values were identified and
permitted classification of gene expression into high / low
for further analysis. JMP v8.0.2 profiling was used for the
identification of associations with histologic grade and with
response to initial treatment. All other analyses were per-
formed with SPSS v.15. Association between binary char-
acteristics was tested using Fisher’s exact test. All tests were
two sided and the level of significance was set at a05 %.
Results
DARPP32 / STAT mRNA Expression in Comparison
to Classic Glioma Parameters
Out of the 145 samples with informative RQ data, amplifi-
cation curves for all five mRNA targets were obtained in
137 cases (DARPP32 was undetectable in 5 and STAT5B in
3 samples). RQ ratios were calculated as described for
DARPP32/STAT1, DARPP32/STAT3, DARPP32/STAT5A,
and DARPP32/ STAT5B; for STAT5B/STAT1, STAT5B/
STAT3, and STAT5B /STAT5A; for STAT3/STAT1, and
STAT3/STAT5A; and, for STAT1/STAT5A.
In general, the relative expression of STAT1, a gene
located on chromosome 2q32 was higher in comparison to
all genes on 17q, i.e., STAT5A and STAT5B on 17q11,
DARPP32 on 17q12, and STAT3 on 17q21 (Fig. 1a). The
expression of DARPP32 and STAT genes was statistically
strongly correlated at the bivariate analysis level (Spear-
man’s p’s<0.0001 in all cases). However, strong correla-
tions with r>0.5 (p<10−6) were only observed for STAT
gene pairs (Fig. 1b). In comparison, all DARPP32/STAT
mRNA ratios inter-correlated with r values >0.8, while
corresponding correlations between STAT ratios were only
occasionally observed and were lower (STAT5B/STAT5A
vs. STAT5B/STAT3, r00.55; STAT5B/STAT5A vs. STAT3/
STAT5A, r00.73; STAT3/STAT5A vs. STAT1/STAT5A, r0
0.56). Among the five genes and in comparison to the eight
available NNBT samples, only DARPP32 mRNA expres-
sion was found significantly decreased in grade II gliomas
(mean±SD: 0.84±1.08 in NNBT vs. 0.26±0.25 in grade II,
p00.0001). STAT gene expression remained constant be-
tween NNBT and grade II tumours. However, although the
DARPP32 / STAT mRNA ratios were also decreased in
grade II as compared to NNBT samples, these did not reach
statistical significance. Hence, a possible bias of the endog-
enous reference (GUSB) could not be excluded for compar-
isons between non-neoplastic and neoplastic brain tissue.
Single marker RQ values and combined marker RQ ratios
were not associated with patient age, while STAT5A mRNA
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was significantly higher in men as compared to women (69
vs. 76, mean±SD: 0.11±0.13 vs. 0.19±0.28, respectively,
p00.0090). The latter may be attributed to the different
regulation of STAT5 regulation in females and in males
[40, 41]. No differences in the expression of the genes
examined or in their RQ ratios were observed in primary
vs. secondary glioblastomas or with respect to the absence
vs. presence of oligodendroglial component, although the
latter category included a small number of tumours only.
Among the 137 samples with informative RQ data for all
targets, 110 corresponded to grade IV, 14 to grade III and 13 to
grade II tumours (in total, 27 non-glioblastomas). STAT1 and
STAT3 mRNA expression did not differ among glioma
grades. By contrast, the remaining genes that were all located
on chromosome 17q, i.e. STAT5A, STAT5B and DARPP32,
were strongly downregulated in grade IV as compared to
grade II tumours (Fig. 2a). The pattern for this change in gene
expression was different for STAT5A and STAT5B as com-
pared to DARPP32. DARPP32 mRNA was downregulated
with progressive degree of malignancy, while the expression
of the two STAT5 genes did not differ in grade II and III
tumours. In accordance to single DARPP32 mRNA expres-
sion, DARPP32/STAT1, DARPP32/STAT3, STAT5A/STAT3
and STAT5B/STAT3 ratios were strongly decreased in grade
IV tumours (Fig. 2b). However, for all expression markers,
several outliers were present, particularly in glioblastomas,
indicating that some of these tumours expressed high levels
of the generally down-regulated DARPP32 and STAT genes.
Indeed, profiling of all above RQ values and ratios revealed
glioma subgroups with high STAT5B/STAT3 & STAT5B/
STAT5A & STAT5B/STAT1 mRNA ratios, high STAT1/
STAT3 and STAT1/STAT5A, and high DARPP32/STAT ra-
tios. Further analysis of these profiles showed that high
DARPP32/STATmRNA ratios clustered together in the entire
glioma series and were more common in non-glioblastomas
(9/27 tumours [33.3 %]) as compared to glioblastomas (12/
110 tumours [10.9 %]) (Fig. 2c). By contrast, STAT mRNA
ratios did not cluster together in the same setting and their
profiles were not associated with glioma grade.
MGMT promoter methylation, a marker associated with
response to temozolomide, was investigated here only in the
group of 67 patients with known follow-up and yielded infor-
mative results in 54 samples (Table 2). Single DARPP32,
STAT1, STAT3 and STAT5A & B mRNA expression and
their ratios were unrelated to MGMT promoter methylation,
as assessed with the Mann–Whitney test. No statistics could
be performed for IDH1 mutations, since these were found in
two tumours only. One of these tumours was a clinically
secondary glioblastoma; the second IDH1 mutant tumour
was an anaplastic astrocytoma (grade III) with histologic
glioblastoma confirmation (grade IV) in a limited area of the
available tissue material. Taking into account that IDH status
was unknown in six cases due to non-informative sequencing,
59 tumours (88 %) were IDH1 and IDH2 wild type in the
DARPP32 vs. STAT1, r=0.37
DARPP32 vs. STAT3, r=0.43 
DARPP32 vs. STAT5A, r=0.45 
DARPP32 vs. STAT5B, r=0.46 
STAT1 vs. STAT3, r=0.67 
STAT1 vs. STAT5A, r=0.58 
STAT1 vs. STAT5B, r=0.61 
STAT3 vs. STAT5A, r=0.68 
STAT3 vs. STAT5B, r=0.82 





















Fig. 1 DARPP32 and STAT
gene expression descriptives.
a The highest relative
expression values were




low. X-axes: RQ values. b Al-
though the expression of all
genes significantly correlated in
the bivariate mode, these corre-
lations were stronger for STAT
(right panel) than for DARPP32
vs. STAT (left panel) gene pairs.
r 0 Spearman’s bivariate corre-
lation coefficient. In a & b,
RQ values were normalized
with GUSB
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cohort with available clinical data. Regarding EGFR CN, the
STAT5B/STAT3 profile was marginally inversely associated
with higher copy numbers of this gene (Mann Whitney p0
0.058), but no further associations with the remaining single
or combined RQ markers were observed.
DARPP32 / STAT mRNA Expression and Activation
of the AKT Pathway in Gliomas
Based on TMA core availability, it was possible to evaluate
AKT phosphorylation at Ser473 in 128/145 cases with
informative RNA data for cytoplasmic positivity and in
133/145 cases for nuclear positivity (in the additional five
cases, positive parts of the cores were preserved). Phosphor-
ylated AKT-S473 was present in the cytoplasm of neoplastic
cells in 52/128 (40.6 %) cases, while it was localized in the
neoplastic nuclei in 24/133 (18.4 %) of the tumours only.
Non-cancerous elements, e.g., endothelial cells, were nega-
tive. Nuclear and cytoplasmic staining was not necessarily
simultaneously present in the same tumour. Nuclear pAKT-
S473 positivity was unrelated to glioma grade but
cytoplasmic positivity was, since 48 out of the 52 tumours
with cytoplasmic pAKT-S473 localization were glioblasto-
mas (p00.001).
Among all gliomas, cytoplasmic pAKT-S473 positivity
was strongly associated with lower DARPP32 (mean±SD:
0.15±0.19 vs. 0.07±0.10) and STAT5A (mean±SD: 0.19±
0.28 vs. 0.10±0.12) expression, as well as with lower
DARPP32/STAT1 (mean±SD: 0.08±0.17 vs. 0.03±0.03),
DARPP32/STAT3 (mean±SD: 0.13±0.21 vs. 0.06±0.09)
and DARPP/STAT5B (mean±SD: 0.40±0.56 vs. 0.16±
0.19) ratios (Fig. 3a). When examined in glioblastomas
only, cytoplasmic pAKT-S473 was again observed in cases
with lower DARPP32 (mean±SD, positive vs. negative
pAKT: 0.12±1.7 vs. 0.06±0.09, p00.0182) and STAT5A
(mean±SD: 0.13±0.12 vs. 0.08±0.07, p00.0316).
DARPP32 / STAT mRNA Expression and the Apoptosis
Inhibitor Survivin (BIRC5)
Survivin is a member of the inhibitors of apoptosis protein









































































































































































Fig. 2 Associations of
DARPP32 and STAT gene
expression with glioma grade.
a Single gene expression
normalized with GUSB.
Among the five genes
examined, DARPP32, STAT5A
and STAT5B were significantly
down-regulated in grade IV in
comparison to grade II and III
tumours, while DARPP32
expression was significantly
different between grade III and
IV tumours as well (Mann–
Whitney test). b DARPP32/
STAT gene expression ratios
(avoiding a possible effect of
GUSB) were also strongly re-
lated to tumour grade (Mann–
Whitney test). However, in line
with (a), many outliers were
observed in glioblastomas
(grade IV tumours). In (c),
profiling of all gliomas (blue:
low; red: high ratios) revealed
non-overlapping subtypes
DARPP32/STAT3 & 5 ratios
clustered in association with
glioma grade (Pearson Chi sq
p00.0031). Marked cases in the
two clusters: non-grade IV
cases
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prognostic factor in several types of cancer, including glio-
blastomas [43], where it has been associated with proliferation
but not with apoptosis [44]. In our series, survivin IHC data
were obtained for 116 gliomas, out of which 75 (63.4 %)
displayed intra-nuclear spot positivity. As previously reported
with different antibodies [36, 37, 43], survivin and Ki-67
positivity were strongly associated (p00.001). Survivin posi-
tivity was also strongly associated with nuclear AKT-Ser473
phosphorylation (Fisher’s exact p00.0028), while a trend was
also observed for cytoplasmic pAKT positivity (p00.0734).
In line with the above data for AKT-Ser473 phosphoryla-
tion, survivin positivity was mostly observed in tumours with
low DARPP32/STAT1 (mean±SD, positive vs. negative sur-
vivin: 0.10±0.22 vs. 0.04±0.06), low DARPP32/STAT3
(mean±SD: 0.16±0.27 vs. 0.08±0.10), and low DARPP32/
STAT5B (mean±SD: 0.52±0.66 vs. 0.22±0.32) (Fig. 3b). In
the group of 92 glioblastomas that were evaluable for survi-
vin, positive tumours (n061) often expressed low DARPP32/
STAT5B (mean±SD, positive vs. negative survivin: 0.42±
0.56 vs. 0.18±0.25, p00.0127), but higher STAT5B/STAT3
(mean±SD: 0.27±0.14 vs. 0.38±0.29, p00.0155).
Relatively High DARPP32 / STAT mRNA Expression
is Favorably Associated with Response to Initial Radiotherapy /
Temozolomide Treatment and has a Positive Effect
on Glioblastoma Patient Survival
Other than expected, MGMT promoter methylation was not
associated with response to treatment (PFS-6 month) in this
study. PFS-6 mo was further unrelated to patient age, gender
and to the extent of surgery. In order to investigate for a
possible impact of the observed alterations on the outcome
of glioblastoma patients, who were all treated with post-
surgery CCRT, we first undertook a profiling screening for
DARPP32 and STAT ratios in the group of 67 patients
(Fig. 4). Very high DARPP32/STAT ratios clustered togeth-
er and did not overlap with high STAT5B/STAT5A,
STAT5B/STAT3 and STAT1/STAT5A. High DARPP32/
p=0.0040 p=0.0144
p=0.0038 p=0.0093 p=0.0153
a     AKT-Ser473, cytoplasmic localization
b    Survivin
p=0.0056 p=0.0086 p=0.0019
Fig. 3 DARPP32 and STAT
gene expression, single or in
paired ratios, is inversely
associated with Akt/PKB
phosphorylation (a) and with
survivin expression (b). In
a, a representative IHC
microphotograph (X400) show-
ing a glioblastoma with cyto-
plasmic localization of
phosphorylated Akt/PKB is
shown. The Mann–Whitney test
was used for all comparisons.
Significant inverse associations
for the same DARPP32/STAT
ratios (shown as Y-axis labels)
were observed for both Akt/
PKB phosphorylation and
survivin. Y axes represent RQ
values
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STAT ratios were observed in 14/67 patients, 13 out of
which responded favorably to CCRT. In comparison, among
the 15 cases with low DARPP32/STAT and high STAT/
STAT ratios, three were non-responders or experienced early
death. Notably, the STAT3/STAT1 ratio did not cluster with
the rest of variables in this profile. Based on these observa-
tions, we then investigated the impact of single mRNA ex-
pression and the corresponding ratios on patient outcome. For
this, we classified gene expression into “high” and “low” by
using ROC curve analysis with PFS-6 mo as the state variable.
Gene expression parameters that failed to yield a significantly
(>0.6) large area under the curve (AUC) were not further used
for survival analysis. The results of ROC curve analysis and
the corresponding cut-off values for gene expression classifi-
cation are shown in Table 3. Parameters that were thus classi-
fied were indeed associated with response to treatment in
patients with glioblastoma (Table 4). It appeared that relatively
high DARPP32 expression (when calculated vs. GUSB), and
relatively high DARPP32 expression ratios with all STAT
genes examined (without GUSB interference) were positively
associated with absence of relapse in 6 months, as well as with
prolonged progression free survival (PFS) (Table 5, Fig. 4).
PFS closely reflected treatment response in the cohort exam-
ined where all patients had received the same initial treatment.
Relatively high STAT5B expression, alone or as STAT5B/
STAT3 ratio, was also favorably associated with patient re-
sponse to CCRT and with prolonged PFS (Fig. 5).
OS is unequivocally the most solid parameter for assess-
ing patient disease course. However, as shown in Table 1,
the administered treatment schemes after the initial course of
radiotherapy / temozolomide were not homogeneous and it
is possible that these affected patient outcome. Nevertheless,
in this group of 67 patients, age and gender were not
associated with disease course. In this context, the most
important factor affecting patient survival was the extent
of surgical removal of the tumours; in cases with total or
subtotal excision (n048), median OS was 20.52 month
(±SD:1.36, 95 % CI: 17.86–23.18) in comparison to cases
where tumours were removed by biopsy only (n019) and
patient OS was 11.6 month (±SD:1.60, 95 % CI: 8.46–
14.75, p00.002). Out of the immunohistochemical parame-
ters tested, none was associated with patient OS. MGMT
promoter methylation was not associated with PFS and
showed only a trend for the methylated tumours and pro-
longed patient survival (p00.088).
Relatively high DARPP32 expression as single parame-
ter (normalized vs. GUSB), high DARPP32/STAT3 and
DARPP32/STAT5A expression ratios, as well as the com-
bined bivariate profile of DARPP32/STAT3 and STAT5B/
STAT3 were strongly associated with longer glioblastoma
patient OS (Table 5, Fig. 5).
Last follow up for the clinically secondary IDH1 p.R132H
mutant glioblastoma was at 28.9 months from this manifesta-
tion with the patient (man, 41 y.o.) alive and well. The IDH1
p.R132G mutant patient (woman, 35 y.o.) with histologically
secondary glioblastoma progressed upon CCRT at 4 months
and succumbed to disease after 18.6 months from diagnosis.
These cases and their DARPP32/STAT profiles are marked in
Fig. 4. The third patient (man, 62 y.o.) with histologically
secondary IDH1 and IDH2 wild-type glioblastoma suc-
cumbed to disease during CCRT at 3.5 months; the tumour
had very low DARPP32/STAT3 ratio (RQ 0.002).
Upon multivariate Cox regression analysis adjusted for
glioblastoma patient age, extent of surgery, and all mRNA
markers presented here, total/subtotal removal of the tumour
(HR: 0.431; 95 % CI: 0.241–0.771, Wald p00.005), high
DARPP32/STAT5B mRNA ratios (HR: 0.341; 95 % CI:
0.169–0.690; Wald p00.003) and high STAT5B/STAT3
mRNA ratios (HR: 0.480; 95 % CI: 0.280–0.824; Wald p0
0.008) were independent favorable parameters for prolonged
Fig. 4 DARPP32 and STAT gene expression ratios were associated
with response to initial CCRT treatment, as assessed with PFS-6 mo.
Marked rows on the left of the colormap correspond to cases where
progression or death was noticed within 6 months (16 out of 67
patients with known follow up). Except for one case, high
DARPP32/STAT ratios were observed in patients who responded well
to CCRT. In comparison, five non-responders were observed among
single or combined high STAT ratios. The two cases marked with black
circles correspond to the two IDH1 mutant tumours, the upper one with
early progression upon CCRT and the lower one with a favorable
outcome. x marks: cases non-informative for IDH1 & 2 sequencing
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PFS. Patient survival was aggravated with increasing age
(HR: 1.028; 95 % CI: 1.003–1.054; p00.029), while extent
of surgery was independently associated with prolonged sur-
vival (HR: 0.198; 95 % CI: 0.101–0.390; p<0.001). In this
setting, high DARPP32/STAT5A mRNA ratios were also
independently predictive for longer survival (HR: 0.320;
95 % CI: 0.160–0.638, p00.001).
Discussion
The present study shows that transcript ratios of DARPP32,
STAT3, STAT5A and STAT5B in glioblastomas are strongly
related to patient outcome. The glioblastomas examined here
can be considered as de novo in 95 % of the cases and were
validated as IDH1 and IDH2 wild-type in 88 % of all patients
with available clinical data. In this group of unfavorable disease
where patients initially received CCRT / temozolomide, tumour
STAT3 mRNA expression lower than STAT5B and DARPP32
Table 3 ROC Curve analysisa data reveal strong associations between
DARPP32 / STAT gene expression and response to temozolomide /









DARPP32/GUSB 0.816 0.0002 0.029
STAT5B/GUSB 0.725 0.0068 0.231
DARPP32/STAT1 0.727 0.0065 0.011
DARPP32/STAT3 0.714 0.0101 0.015
DARPP32/STAT5A 0.749 0.0028 0.169
DARPP32/STAT5B 0.670 0.0409 0.024
STAT5B/STAT3 0.673 0.0381 0.281
a Receiver Operating Characteristic (ROC) Curve analysis was per-
formed to classify gene expression according in patients having
achieved a 6moPFS upon treatment initiation
b Cut-off was calculated as the value with the highest sensitivity and
specificity for the prediction of achieving 6 months without relapse
from treatment initiation. High vs. low 0 >cut-off vs. ≤cut-off
Table 4 Classification of gene
expression according to ROC
Curve cut-offs is strongly asso-
ciated with 6moPFS
aFisher’s exact test
Relative gene expression N Relapse
free 6 mo
Relapse or








>0.230 38 5 0.0027
DARPP32 & STAT5B 66
all other 21 15
both high 29 1 0.0003
DARPP32/STAT1 67
≤0.010 15 11
>0.010 36 5 0.0077
DARPP32/STAT3 67
≤0.015 10 10
>0.015 41 6 0.0034
DARPP32/STAT5A 67
≤0.169 6 10
>0.169 45 6 0.0001
DARPP32/STAT5B 67
≤0.024 4 7
>0.024 47 9 0.0024
STAT5B/STAT3 67
≤0.281 19 12
>0.281 32 4 0.0106
DARPP32/STAT3 & STAT5B/STAT3 67
all other 24 14 0.0079
both high 27 2
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was associated with better prognosis upon standard treatment.
STAT3 mRNA expression was abundant in glioma tissues and
did not differ among glioma grades, which is of no surprise
since STAT3 functions in a pro- or anti-tumour mode depend-
ing on its molecular environment [15, 16]. The present findings
further support STAT3 as an unfavorable prognosticator in
glioblastomas [16, 45], and are in line with its mesenchymal-
subtype-promoting role, as has been shown with different
approaches [9, 15, 46, 47]. Response measured as 6moPFS,
and PFS itself, seem to be more reliable endpoints for assessing
the markers examined here than OS, which may have been
influenced by the subsequent treatment lines administered to
about 40 % of the patients. Thus, the fact that STAT3 ratios did
not maintain their significance as prognostic for OS may indi-
cate that the favorable effect of relatively low STAT3 is therapy
related. STAT3 inhibition was shown to restore temozolomide
resistance in glioblastoma cells [48]. Overall, the present and
previously published data support STAT3 inhibition for thera-
peutic purposes in glioblastoma, possibly in combination with
other drugs [48, 49].
The Stat5 proteins have been described as downstream
targets of EGFRvIII [50] contributing along with STAT3 to
the escape of glioblastoma from microglial surveillance
[51], without distinguishing between Stat5a and 5b mole-
cules. STAT5A, STAT5B, and STAT3 reside in close neigh-
borhood on chromosome 17q and as shown here, their
expression is strongly correlated. Regarding their relative
mRNA expression against DARPP32 and STAT3, STAT5A
and STAT5B appeared to have different although not con-
trasting effects on patient outcome in this study, which has
been reported for epithelial cancers [52]. Like STAT3, our
findings on STAT5B are in accordance with its previously
published pro-oncogenic role in glioblastomas [18]. Accord-
ing to the present data, STAT3 effects may depend on
STAT5B expression, with high STAT5B/STAT3 ratios being
associated with a more indolent glioblastoma course. Rele-
vant information in gliomas is missing but in breast cancer
STAT5 and STAT3 mediate opposing effects on several key
target genes, with STAT5 exerting a dominant role [53]. The
present data on STAT5B and STAT3 may be useful when
Table 5 Effect of relative DARPP32 and STAT expression profiles on the outcome of patients with high grade gliomas















low 27 14.82 1.65 11.59–18.05 0.0318 6.07 1.19 3.73–8.40 0.0002
high 39 19.90 1.71 16.56–23.25 12.62 2.22 8.27–16.98
STAT5Ba
low 24 13.25 1.85 9.63–16.87 0.0875 6.49 0.72 5.08–7.91 0.0046
high 43 18.92 1.70 15.58–22.25 12.82 1.20 10.47–15.17
DARPP32/STAT1
low 26 14.23 2.47 9.40–19.06 0.0865 6.56 2.86 0.95–12.17 0.0371
high 41 18.92 1.76 15.46–22.38 11.84 2.63 6.68–16.99 0.0446
DARPP32/STAT3
low 20 13.25 3.84 5.73–20.77 0.0424 5.18 1.21 2.81–7.55 0.0066
high 47 18.59 2.12 14.43–22.75 11.61 2.04 7.60–15.61
DARPP32/STAT5A
low 16 6.98 3.21 0.69–13.28 0.0120 4.75 0.26 4.24–5.27 0.0008
high 51 18.59 2.23 14.23–22.95 11.61 1.62 8.43–14.79
DARPP32/STAT5B
low 11 9.67 4.60 0.65–18.69 0.1169 4.98 0.25 4.49–5.48 0.0016
high 56 18.20 2.24 13.81–22.59 10.36 1.51 7.40–13.33
STAT5B/STAT3
low 31 17.18 2.77 11.76–22.60 0.0981 7.57 1.26 5.11–10.04 0.0048
high 36 16.62 2.78 11.18–22.07 12.13 1.60 9.00–15.26
DARPP32/STAT3 & STAT5B/STAT3
all other 38 15.15 1.68 11.86–18.44 0.0293 7.57 1.69 4.26–10.89 0.0004
both high 29 19.90 3.42 13.20–26.60 12.82 3.82 5.34–20.30
a Relative expression assessed vs GUSB
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assessing these molecules for pharmacologic interactions in
glioblastomas.
From a different perspective, the most interesting findings in
this study concern DARPP32, which, to the best of our knowl-
edge, has not merited attention in brain tumours before but
seems worth investigating in this context. It is shown here that
DARPP32 is expressed at low levels in gliomas while its
expression is further decreased with progressing degree of
malignancy. DARPP32 is a key marker of neural specialization
marking, for example, differentiation of human embryonic
stem cells into specialized neurons [54]. One possible short-
coming regarding our findings is that with the assay used we
detected all DARPP32 splice variants; hence, we cannot report
on t-DARPP expression. This isoform is pro-oncogenic but
nevertheless expressed along with full-length DARPP32, while
it is not reported as expressed in the central nervous system
[55]. In addition, although it cannot be excluded that DARPP32
expression may derive from entrapped neurons in low grade
tumours (for example, in grade II tumours), such an argument













Fig. 5 Effect of DARPP32
and STAT gene expression on
glioblastoma patient outcome.
a progression-free survival
(PFS); b overall survival (OS)
Significant gene expression
ratios are shown. High—low
classification of RQ values
according to ROC curve
cut-offs; combined vs. STAT3:
DARPP32/STAT3 and
STAT5B/STAT3; p: log rank
test
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express this molecule at levels resembling grade II tumours.
Considering that glia has neurotrophic, neuroprotective and
synaptogenic function, as well as a major role in neural stem
cell differentiation (reviewed in [56]), the observed DARPP32
expression reflecting “neuronal” features in gliomas may in-
dicate some retained degree of differentiation in the neoplastic
cells. Overall, our findings with DARPP32 ratios also seem to
be in line with previous observations on neuronal-like profiles
mainly in the neural, and less so in the classical and mesen-
chymal subtypes, which correspond to tumours with worsen-
ing prognosis in this order [9]. It is currently unknown
whether DARPP32 is translated into protein and how it func-
tions in gliomas, in particular with respect to its normal role as
an integrator of neurotransmission. In addition, there is a gap
in the literature regarding dopamine and monoamine signaling
in general in these tumours. However, since dopaminergic
compounds inhibit the growth of glioblastoma stem cell
enriched cultures [57], the functional aspects of DARPP32
expression in gliomas and the neuronal characteristics of
glioblastomas seem worth further pursuing.
A protective role of DARPP32 and an aggravating role of
STAT3 and STAT5B in glioblastomas are further supported by
the association of the corresponding mRNA ratios with AKT/
PKB phosphorylation and survivin expression. Survivin ex-
pression is associated with proliferation and poorer prognosis
in glioblastomas [43, 44], while it depends on STAT3 [28, 29].
AKT is phosphorylated at Ser473 by the rictor-mTOR complex
[58], which may be inhibited experimentally in glioblastoma
cells [59], while inhibition of AKT activation results in growth
cessation of glioma cells [60]. These IHCmarkers did not have
an effect on patient survival in the present series. It should be
noticed that survivin is a protein with very short half-life [61],
while the performance of the antibody used for phospho-AKT
largely depends on time-to-fixation [62]. Hence, IHC results
for these markers may not reflect the actual condition of these
proteins in tumours, in spite that every care was taken for
prompt tissue fixation upon surgical removal Nevertheless,
high DARPP32/STAT1, DARPP32/STAT3 and DARPP32/
STAT5B ratios were associated with the absence of phosphor-
ylated AKT and survivin in the tumours examined, indicating
that DARPP32 negatively and STAT positively interfere with
the expression of these pro-oncogenic protein markers.
The value of the present findings is that they potentially
represent markers for the assessment of IDH-wild-type glio-
blastomas with unfavorable prognosis. Clearly, these results
need prospective validation in larger multi-center sample and
patient cohorts. In terms of methodology, the approach used
here allows for the evaluation of glioma-relevant gene expres-
sion ratios without the involvement of a reference gene, which
was used only for template evaluation. In a sense, this ap-
proach may be described as a clustering pre-stage, since it
allows for gene expression ratios to be examined in duets.
From a different aspect, mRNA ratios may be described as
yin-yang: since molecules act in concert, their ratios may be
more important than individual up- or down-regulation, which
can not be determined by this approach. DNA / RNA extrac-
tion from routine FFPE diagnostic material is increasingly
applied in pathology labs, while RT-qPCR is a very robust
method for obtaining quantitative results. One of the problems
with such results is the assessment of cut-offs. With the ROC
curve cut-offs applied here, DARPP32 and STAT5B tran-
scripts should be roughly higher than STAT3 transcripts by
2 % and 25 %, respectively, for the classification of favorable
vs. unfavorable ratios. Although these results are unavoidably
fitted to the cohort, as would be the case with any single
continuous marker (including clusters that derive from such
assessments), these analogies are easier to keep when stan-
dardizing the method.
Given the heterogeneity of gliomas and the devastating
course of glioblastomas, glioblastoma subtyping is necessary
for a more efficient assessment of patients for the application
of individualized treatment [63]. With all subtyping efforts so
far, which may be replicated retrospectively but seem to suffer
from inherent errors for wide application [64], the best as yet
distinction of glioblastomas appears to be IDH positive and
negative disease [6, 7]. This study provides an applicable
approach for the patient stratification in addition to IDH
mutations. The DARPP32/STAT ratios presented here seem
worth for further testing as prognostic and potentially as
markers predictive for response to standard, as well as to
new drug combinations for glioblastoma treatment. The neu-
ronal aspect of glioma differentiation, in particular glioblasto-
ma, as evidenced with DARPP32 expression, merits further
elucidation for understanding the behaviour of these tumours.
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